Myelofibrosis medical therapy: Difference between revisions

	Myelofibrosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Myelofibrosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Myelofibrosis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Myelofibrosis medical therapy All Images X-rays Echo and Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Myelofibrosis medical therapy
CDC on Myelofibrosis medical therapy
Myelofibrosis medical therapy in the news
Blogs on Myelofibrosis medical therapy
Directions to Hospitals Treating Myelofibrosis
Risk calculators and risk factors for Myelofibrosis medical therapy

Revision as of 15:28, 10 March 2016

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]

@@ Line 1: / Line 1: @@
 __NOTOC__
 {{Myelofibrosis}}
-{{CMG}}
+{{CMG}}{{AE}}{{SR}}
 ==Overview==
 ==Medical therapy==
-Other treatment options are largely supportive, and do not alter the course.<ref name="pmid18185525">{{cite journal |author=Kröger N, Mesa RA |title=Choosing between stem cell therapy and drugs in myelofibrosis |journal=Leukemia |volume=22 |issue=3 |pages=474–86 |year=2008 |month=March |pmid=18185525 |doi=10.1038/sj.leu.2405080 |url=http://dx.doi.org/10.1038/sj.leu.2405080}}</ref> These options may include regular [[folic acid]], [[allopurinol]] or [[blood transfusion]]s. [[Dexamethasone]], alpha-[[interferon]] and [[hydroxycarbamide]] may play a role.
-[[Lenalidomide]] and [[Thalidomide]] may be used in its treatment, though they can cause [[gout]] and leave the patient susceptible to diseases such as [[pneumonia]].
-Frequent [[blood transfusions]] may also be required.
-The patient with the myelofibrosis should be tested for [[Tuberculosis]] even if the patient doesn't manifest the symptoms of TB. There is strong evidence of myelofibrois improvement with the antituberculous treatment.
 ==References==
@@ Line 20: / Line 13: @@
 [[Category:Types of cancer]]
 [[Category:Hematology]]
+[[Category:Oncology]]
 {{WikiDoc Help Menu}}
 {{WikiDoc Sources}}